Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.15
+0.39001.88%
Post-market: 21.150.00000.00%16:20 EDT
Volume:2.33M
Turnover:48.90M
Market Cap:1.88B
PE:-5.19
High:21.71
Open:21.09
Low:20.15
Close:20.76
Loading ...

Travere Therapeutics Inc : TD Cowen Raises Target Price to $30 From $24

THOMSON REUTERS
·
21 Feb

Travere Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview

Reuters
·
19 Feb

Industry Analysts Just Made A Substantial Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Revenue Forecasts

Simply Wall St.
·
14 Feb

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
14 Feb

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
13 Feb

Evercore ISI Keeps Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
13 Feb

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
13 Feb

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
13 Feb

Travere Therapeutics (TVTX) Gets a Buy from Scotiabank

TIPRANKS
·
12 Feb

U.S. RESEARCH ROUNDUP-Edison International, Onestream, Vertex Pharmaceuticals

Reuters
·
12 Feb

Sector Update: Health Care Stocks Fall in Late Afternoon Trading

MT Newswires Live
·
12 Feb

Top Midday Gainers

MT Newswires Live
·
12 Feb

Wedbush Raises Price Target on Travere Therapeutics to $30 From $26, Maintains Outperform Rating

MT Newswires Live
·
12 Feb

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Dow Jones
·
11 Feb

Travere Therapeutics Completes US FDA Meeting Ahead of Potential Kidney Disease Drug Submission

MT Newswires Live
·
11 Feb

Travere Therapeutics to submit sNDA for FILSPARI in FSGS

TIPRANKS
·
11 Feb

Travere Therapeutics to Submit Snda for Filspari® (Sparsentan) in Fsgs

THOMSON REUTERS
·
11 Feb

Wedbush Lifts Price Target on Travere Therapeutics to $26 From $25, Keeps Outperform Rating

MT Newswires Live
·
23 Jan

Evercore ISI Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
16 Jan

Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
15 Jan